Floatz logo

Palifosfamide-Tris

Thymoma

Alaunos TherapeuticsPhase 1Dormant
CC
42/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
27/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Thymoma cohort.

Asset / SponsorPhaseRating
Avelumab
National Cancer Institute (NCI)
Phase 2CCC
IMMUNOGLOBULIN HALF-IG G1-KAPPA/SCFV-H-CH2-CH3, ANTI-(HOMO SAPIENS CTLA4 (CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4, CD152)) AND ANTI-(HOMO SAPIENSPDCD1 (PROGRAMMED CELL DEATH 1, PD-1, PD1, CD279)), MONOCLONAL ANTIBODY, BISPECIFIC
Xencor, Inc.
Phase 1CC
Bosutinib
Nagla Abdel Karim
Phase 1CC
Doxepin
Mayo Clinic
Phase 2C

Same molecule, other indications

Palifosfamide-Tris is also rated in:

small cell lung carcinomaDormant
B
Indicative ·
57 / 100
View asset →
breast cancerDormant
CCC
Indicative ·
48 / 100
View asset →
adult central nervous system germ cell tumorDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →